SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals informs about newspaper publication

20 Mar 2026 Evaluate
SMS Pharmaceuticals has informed that as per the SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026 a ‘Special Window’ has been re-opened for the relodgement of share transfer requests in physical mode. This facility is only applicable to those transfer deeds that were lodged prior to the deadline of 01st April, 2019 and were either rejected, returned or not processed due to deficiencies in documentation or other procedural lapses. The window shall remain open for a period of one year i.e. from February 5, 2026 to February 4, 2027.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×